Navigation Links
Researchers uncover gene's role in rheumatoid arthritis, findings pave way for new treatments
Date:1/24/2013

ANN ARBOR, Mich. University of Michigan research sheds new light on why certain people are more likely to suffer from rheumatoid arthritis paving the way to explore new treatments for both arthritis and other autoimmune diseases.

The new UMHS research in mice identifies how a specific group of genes works behind the scenes to activate the bone-destroying cells that cause severe rheumatoid arthritis, a debilitating health issue for millions of Americans.

"We believe this could be a significant breakthrough in our understanding of why certain genes are associated with higher risk of rheumatoid arthritis and other autoimmune diseases a link that has been a mystery in the field for decades," says lead author Joseph Holoshitz, M.D., professor of internal medicine and associate chief of research in the division of rheumatology at the U-M School of Medicine.

"We hope that this improved understanding will open the door to future design of drugs to treat this crippling disease and autoimmune disease in general."

The research appeared in The Journal of Immunology and was highlighted by Nature Reviews Rheumatology.

Rheumatoid arthritis is a chronic inflammatory disorder that damages the lining of joints and causes bone erosion, joint deformity and disability. The disease is an autoimmune disorder, characterized by the body's immune system mistakenly attacking the body's tissues.

Researchers have long studied the phenomenon of why certain versions of an inherited group of genes known as "human leukocyte antigen" (HLA) are associated with autoimmune disorders. One subset of these HLA genes that codes a protein sequence called "shared epitope" represents the most significant genetic risk factor for rheumatoid arthritis, affecting disease susceptibility and severity. However, until now, the reason for this strong link has been unclear.

A common theory in the field has been that the association between particular HLA genes and autoimmune diseases is a result of mistakenly identifying body tissues as foreign making the body the target of the immune system and setting off an attack on self-tissues, which results in disease.

The UMHS research challenges this long-held theory. The study shows, for the first time, how this subset of HLA genes causes arthritis by activating inflammation-causing cells, as well as bone-destroying cells (known as osteoclasts). This leads to severe arthritis and bone erosion.

"We showed how the shared epitope is directly triggering osteoclasts, the very cells that are responsible for joint destruction in people with the disease," says Holoshitz.

"Understanding these mechanisms at play could be a significant piece of future drug development. Because we now know the molecular mechanism that activates arthritis-causing cells, we have the potential to block that pathway with simple chemical compounds that could be used to treat rheumatoid arthritis and other diseases."


'/>"/>

Contact: Beata Mostafavi
bmostafa@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Related medicine news :

1. New drug improves survival in multiple myeloma relapse, Moffitt Cancer Center researchers say
2. Researchers discover promising prognostic marker for aggressive breast cancer
3. Researchers design a new imaging technique for identifying the age and sex of a corpse
4. Researchers map emotional intelligence in the brain
5. Researchers find that simple blood test can help identify trauma patients at greatest risk of death
6. Mayo Clinic researchers identify enzyme involved in deadly brain tumors
7. UNC researchers use luminescent mice to track cancer and aging in real-time
8. Gothenburg researchers make world top 10
9. Autism Researchers Surprised by Impaired Brain Connections
10. Researchers identify ways to improve quality of care measurement from electronic health records
11. Researchers identify genetic mutation for rare cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers uncover gene's role in rheumatoid arthritis, findings pave way for new treatments
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... Breast Cancer Conference from Sept. 18 to 20. , The two-day conference is ... subtype with the goal of improving patients’ lives and eliminating racial breast cancer-related ...
(Date:6/23/2017)... Monica, CA (PRWEB) , ... June 23, 2017 , ... ... as the endorsed amalgam separator supplier for CDA members. As part of the amalgam ... reduced price of $99, saving more than $400 off the retail value. This partnership ...
(Date:6/23/2017)... San Francisco, CA (PRWEB) , ... June 23, 2017 , ... ... Conference on 26th June, 2017 from 9 am to 3 pm to present to ... curriculum. The program is an original curriculum project led by The Health Improvement ...
(Date:6/23/2017)... Gilmer, TX (PRWEB) , ... June 23, 2017 , ... ... consultations to residential and business clients throughout eastern Texas, is announcing the launch of ... , Recent breast cancer statistics in the United States reveal that an estimated ...
(Date:6/22/2017)... Miami, FL (PRWEB) , ... June 22, 2017 , ... ... has received more than $245,000 in grant funding to support its programs focused on ... recently, Branches, Inc. was awarded a grant by the Foundation of $15,000 to support ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)...  Novavax, Inc., (Nasdaq: NVAX ) today announced ... of its RSV F protein recombinant nanoparticle vaccine candidate (RSV ... published in the journal Vaccine (the ... scientific conferences). The Company previously announced top line results ... the RSV F Vaccine with the goal of protecting infants ...
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq: ... care, today announced new findings demonstrating positive biochemical outcomes ... System One™. The data will be presented at ... Madrid, Spain . ... Improve Home Dialysis Network in Europe ...
(Date:5/29/2017)...  Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: ... functional selection of stem cells, today provided a corporate ... ended March 31 st , 2017. ... first quarter of 2017," said Dr. Shai Yarkoni, Chief ... treatment of the first blood cancer patient in the ...
Breaking Medicine Technology: